There is no FDA-approved Semax nasal spray and no established U.S. Semax dosage. Human studies exist, but they are small, mostly Russian-language, use different regimens and do not establish a general dose for cognition, ADHD, migraine or self-treatment. The FDA's 2026 review concluded that the evidence weighed against adding Semax free base or acetate to the section 503A bulks list.
What Semax dosage has been used in human studies?
The clearest indexed regimen is 6,000 micrograms per day in a 2018 post-stroke rehabilitation study. The 110 participants received two 10-day courses separated by 20 days. That amount is reportable as a study fact, but it belongs to adults recovering after ischemic stroke under a research protocol—not to healthy people seeking a nootropic effect.
Why a study amount is not a Semax dosing protocol
A protocol answers a narrow research question in a selected population. A standard dose requires a reproducible product, dose-ranging evidence, clinical endpoints, contraindications and enough safety data to define who should not receive it. The published Semax record does not supply that chain for the uses most vendor pages advertise.
The FDA review found no supporting literature for ADHD, treated “nootropic” claims as part of the cerebral-ischemia review because no clinical indication could be defined, and noted that approved alternatives already exist for the evaluated conditions. It also found insufficient data to resolve risks including immunogenicity, aggregation and peptide-related impurities.
How do you calculate micrograms per spray?
Use two verified inputs: concentration in micrograms per millilitre and pump delivery in millilitres per actuation. Multiply them. A 1,000 mcg/mL solution delivered by a calibrated 0.1 mL pump would contain 100 mcg per actuation. If the pump delivers 0.07 mL, the same solution contains 70 mcg per actuation.
That arithmetic does not select a dose. It only audits a label claim. Percentage notation can be converted too—1% weight/volume conventionally means 10 mg/mL—but a compounded nasal product still needs a qualified device and verified content uniformity before a calculated amount becomes a reliable delivered amount.
Why the nasal-spray device matters
The FDA treated the pump as a critical component, not packaging. Its review listed pump delivery, content uniformity, spray pattern, plume geometry and droplet-size distribution as quality attributes. It also found no proposed control strategy covering the container, microbial quality, particulates, leachables or compatibility between the device and Semax formulation.
Those gaps explain why copying a vendor concentration into a generic “sprays per dose” chart overstates what is known. A bottle can contain the claimed total and still deliver inconsistent actuations. A reconstituted injectable-vial calculator cannot solve a nasal pump problem.
Is Semax FDA approved or lawfully compounded?
It is not FDA approved. The 2026 FDA briefing document states that neither Semax free base nor Semax acetate has a USP or National Formulary monograph and neither is a component of an FDA-approved drug. The agency's evaluation weighed against placing either substance on the 503A bulks list.
The chemistry problem is unusually concrete: nominators gave inconsistent identities for free base and acetate, while FDA noted the two are different bulk drug substances. The agency lists molecular weights of 813.93 g/mol for free base and 874.0 g/mol for the acetate form. A label that says only “Semax” may therefore leave the active material itself ambiguous before dose calculation even begins.
What should a Semax nasal spray label contain?
- The exact substance—free base or acetate—not only the common name.
- Total amount and final concentration in mass per millilitre.
- Metered volume per actuation and the number of labelled actuations.
- Lot-specific identity, purity, sterility and microbial-quality information.
- Storage and beyond-use information tied to that exact formulation and device.
Missing any of the first three prevents independent dose verification. Missing the remaining items prevents the arithmetic from answering whether the product remains what the label says. For vial arithmetic in products where the inputs are known, use the peptide reconstitution calculator; it deliberately does not pretend to validate nasal delivery.